Abstract:Objective To compare the efficacy and safety of short course and high-dose Dexamethasone (HDD) and conventional Prednisone as first-line strategy for children newly diagnosed as primary immune thrombocytopenia (ITP). Methods This study analyzed pre-experimental data of a single center prospective randomized controlled clinical trial.Newly diagnosed but untreated ITP patients enrolled at the Department of Blood and Cancer Center, Beijing Children's Hospital, Capital Medical University from November 2016 to May 2017 were randomized into HDD group[Dexamethasone 0.6 mg/(kg·d), intravenous injection for 4 days]and Prednisone group[Prednisone 2 mg/(kg·d) for 14-28 days and then tapered within 1-2 months, the course of treatment less than 3 months]. Initial response, sustained response and adverse effects after therapy were observed in 2 groups. Results Sixty-six children with ITP were included in the study: 32 patients were in the HDD group and 34 patients were in the Prednisone group.Two groups were matched in the baseline characteristics including gender, age, platelet counts and disease course before therapy and bleeding assessment (all P>0.05). The initial response (the response of HDD group within 10 days of treatment and Prednisone group within 28 days of treatment): overall initial response had no statistical difference between the HDD group and the Prednisone group[90.6%(29/32 cases) vs.100.0%(34/34 cases), χ2=1.528, P>0.05]. HDD group had a lower incidence of complete response compared with that in the Prednisone group[54.4%(19/32 cases) vs.94.1%(32/34 cases), χ2=11.330, P=0.001]; median time of response in two groups showed no statistically difference (2 d vs.1 d, Z=-0.149, P>0.05). There was no significant difference in the recovery of skin and mucosal bleeding after treatment between the Dexamethasone group and the Prednisone group (Z=-1.413, -1.031, all P>0.05). The sustained response (the response lasted for up to 6 months and above): overall and complete sustained response had no statistically difference between the HDD group and the Prednisone group [92.9%(26/28 cases) vs.85.3%(29/34 cases), P=0.594; 78.9% (15/19 cases) vs.81.3%(26/32 cases), P=1.000]. Log-rank test showed no significant difference in the duration of response between 2 groups (P=0.341). The side effects in the Prednisone group included weight gain or Cushing sign (94.1%) and mental and emotional changes (23.5%); in the HDD group 15.6% of children had infection, without other glucocorticoid-related side effects.There was no significant difference in the incidence of infection between two groups[15.6%(5/32 cases) vs.26.5%(9/34 cases), P=0.281]. All of the above infections were of respiratory tract infections and mild gastrointestinal infections. Conclusions Efficacy of the HDD group in the initial and sustained responses is similar, but side effects were apparently lower compared with that in the Prednisone group.However, a large multicenter randomized controlled clinical study is necessary to confirm this result. Key words: Dexamethasone; Child; Immune thrombocytopenia; First-line therapy

Study of Efficacy of Single Low-Dose Intravenous Immunoglobulin in Elevating Platelet Counts

The Change in Number of Platelet and Megalokaryocyte in Children with Idiopathic Thrombocytopenic Purpura after Treatment

Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases.

Treatment of Childhood Idiopathic Thrombocytopenic Purpura with High-Dose Immunoglobulin

[Efficacy and Safety of Low-Dose Rituximab Combined with Different Dosage of Glucocorticoids for Immune Thrombocytopenia].

The Short-Term Responses Between High Dose Methylprednisolone and High Dose Intravenous Immunoglobulin As Initial Therapy for Severe Idiopathic Thrombocytopenic Purpura in Adult

Lower Dosages of Intravenous Immunoglobulin (IVIg) in Treating Immune Thrombocytopenia with Long-Term Follow-up of Three Years

Clinical Study on Recombinant Human Thrombopoietin in Treatment of Children with Primary Immune Thrombocytopenia

Influence of Infections on Immunoglobulin and Glucocorticoid Efficacy in Children with Idiopathic Thrombocytopenic Purpura

[Eltrombopag for the Treatment of Primary Immune Thrombocytopenia in 23 Pediatric Patients].

WITHDRAWN: the Efficacy of Different Dose of Intravenous Immunoglobulin in Treating Acute Idiopathic Thrombocytopenic Purpura: A Meta-Analysis of 13 Randomized Control Trials

Clinical Analysis on Children Acute Thrombocytopenia-absent Radii Syndrome (ITP)

Efficacy and Safety Analysis of Combination Therapy Consisting of Intravenous Immunoglobulin and Corticosteroids versus Respective Monotherapies in the Treatment of Relapsed ITP in Adults

Can low-dose intravenous immunoglobulin be an alternative to high-dose intravenous immunoglobulin in the treatment of children with newly diagnosed immune thrombocytopenia: a systematic review and meta-analysis

[A clinical comparative study on treatment of severe newly diagnosed immune thrombocytopenia by recombinant human thrombopoietin combined with glucocorticoid].

Classificatory Treatment of Refractory Idiopathic Thrombocytopenic Purpura

Observation on the high dose dexamethasone combined with recombinant human interleukin-11 in the treatment of the patients with newly diagnosed primary immune thrombocytopenia

Excessive Expressions of T Cell Activation Markers in Pediatric Immune Thrombocytopenia

Efficacy and safety of short course high-dose Dexamethasone as first-line treatment regimen for childhood newly diagnosed immune thrombocytopenia

Evaluation of IVIG response in relation to Th1/Th2 cytokines in pediatricm immune thrombocytopenia.

Efficacy and Safety of High Dose Recombinant Human Thrombopoietin in the Treatment of Immune Thrombocytopenia